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Herbs and spices of natural origin have been used traditionally for culinary and therapeutic purposes. Ursolic acid, a 
pentacyclic triterpenoid, is a major component of various foods, herbs and spices utilized in daily life. The purpose of this 
study was to investigate the cardio-protective action of ursolic acid against cardio-toxicity induced by cyclophosphamide. 
Animals were randomly divided into control group (1% dimethyl sulfoxide, s.c.), toxic control (Cyclophosphamide 200 
mg/kg, i.p.), ursolic acid treated (40 mg/kg, s.c.) and ursolic acid-cyclophosphamide combination treatment. Animals were 
sacrificed at the end of the treatment period and biochemical, electrocardiographic and histopathological changes were 
measured. Cyclophosphamide treatment showed marked increase in biomarker enzymes (CKNAC, CKMB, LDH, AST, and 
ALT), decreased tissue antioxidants (SOD, catalase & GSH), hyperlipidemia (TC, TG) and abnormal electrocardiographic 
(HR, RR, QRS, QT & PR intervals) and histopathological changes. Ursolic acid treatment restored tissue antioxidants, 
normalised biochemical and electrocardiographic parameters and prevented structural damage of the myocardium. Findings 
from this study indicate the protective role of ursolic acid against cardiotoxicity caused by cyclophosphamide. 
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Herbs and natural products have been used since 
ancient times in treatment of different ailments1. 
Natural products and products derived from them 
possess a wide array of biological activities. 
Flavonoids, triterpenoids and polyphenolic 
compounds are the primary anti-oxidants of a number 
of natural products2. Additionally, these herbs, spices 
and other naturally derived products find use in 
culinary, cosmetic and medicinal intentions3. They are 
used extensively around the world to enhance flavor, 
color and for conservation of food. Different 
phytoconsitutents of therapeutic interest can be found 
in herbs and spices3,4. It is believed that the most 
effective approach to discovery and development of 
newer drugs is to explore the biological sources for 
new active molecules that treat multitude of diseases5.  
The phytoconstituent, ursolic acid (URSO), is a 
pentacyclic triterpenoid carboxylic acid found 
abundantly in medicinal plants, herbs and foods4–7. 
Major sources of the phytoconstituent are  
apple peels, rosemary, thyme, ocimum species  
and various different herbs and spices5,6,8.  
It possesses multiple beneficiary effects  
including anti-diabetic4, anti-hyperlipidaemic9, 
hepatoprotective10, neuroprotection11 and neuro-
regeneration12 and antibacterial13 among many others. 
It has a complex mechanism of action, which 
includes: attenuation of H2O2 and MPP (1-Methyl-4-
phenylpyridinium) induced impairment in catalase 
and superoxide dismutase (SOD) activity14; 
prevention of lipid peroxidation14; protection of DNA 
against oxidative damage15 and inhibition of nitric 
oxide (NO) production16. 
Occurrence of cardio-toxicity during chemotherapy 
with cytotoxic drugs is of high prevalence and is a 
dose limiting factor in cancer treatment17,18. 
Cyclophosphamide (CYP) is widely used for 
treatment of various leukemias, myelomas, and 
lymphomas. However, its use is limited due to its 
cardiotoxic potential19. CYP is an alkylating 
anticancer drug that acts by cross-linking DNA20. 
Cyclophosphamide causes acute cardio-toxicity with 
signs and symptoms of myopericarditis, which 
manifests into fatal complications, like cardiac 
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tamponade, congestive heart failure, arrhythmias, 
etc.19,21. In the body, CYP is broken down into 
Phosphoramide mustard and Acrolein22. These 
metabolites cause formation of free radicals that cause 
irreversible myocardial tissue injury by damaging 
mitochondria and its capacity to detoxify reactive 
oxygen species (ROS)23, causing for the need of an 
anti-oxidant therapy.  
Research suggests that URSO actively prevents 
ethanol-induced24 and doxorubicin-induced25 
oxidative stress and isoproterenol-induced myocardial 
ischemia26. Studies have also found URSO to act 
through uncoupling of antioxidants and mitochondria 
in isolated hearts27. It is also proven to inhibit nuclear 
factor-kappaB activation induced by ROS produced 
from metabolism of carcinogenic agents and thus 
preventing tumorigenesis28. Ursolic acid prevents 
activation of cyclooxygenase-2 (COX-2), 
lipoxygenase, and inducible nitric oxide synthase 
(iNOS), major factors of inflammation and tissue 
injury by down-regulating of nuclear factor-kappaB5. 
URSO is also known to alter the expression of lipid 
metabolism genes and for enhancing the binding of 
PPAR-α receptors, leading to alterations in hepatic 
lipid metabolism29. 
The occurrence of fatal cardio-toxicity even on a 
single dose of CYP warrants the development of 
cardio-protective regimens that would not only 
prevent the generation of immediate toxic changes but 
also not produce adverse effects of their own. 
Products such as isolated phytoconstituents of natural 
origins play an important part in this setting. These 
phytoconstituents are more potent and induce less 
toxic effects than their synthetic chemically produced 
counterpart drugs30–32. In this study, we have used 
isolated pure ursolic acid to evaluate the cardio-
protective effect of the pure compound against 
cardiomyopathy induced by alkylating 
anticarcinogenic agents like cyclophosphamide.  
 
Materials and methods 
 
Experimental Protocol 
All experiment protocols involving animals were 
conducted according to the principles stated in the 
Guide for the Care and use of Laboratory Animals33 
and CPCSEA Guidelines34. The protocol was 
approved by the Institutional Animal Ethics 
Committee (certificate number: SDCP/IAEC-
09/2012-13). Twenty-four male wistar rats weighing 
between 200-300g and approximately of 7-9 weeks of 
age were procured from and housed at Shree Devi 
College of Pharmacy, Mangalore, India. The cages 
had paddy husk bedding and were maintained at 
25±5ºC under 12 h light-dark cycles. The animals had 
access to purified water and feed. Animals were 
acclimatized to laboratory conditions for at least one 
week before starting the experiment. They were then 
divided into four groups of six animals each: 
 
 Group I (Normal Control): 1% dimethyl 
sulfoxide (s.c.) for 10 days. 
 Group II (CYP): CYP (200 mg/kg, i.p.) on  
Day 1. 
 Group III (URSO): Ursolic acid dissolved in 1% 
DMSO (40 mg/kg body weight, s.c.) for 10 
days.  
 Group IV (CYP+URSO): Cyclophosphamide 
(200 mg/kg, i.p.) on Day 1 and ursolic acid 
dissolved in 1% DMSO (40 mg/kg body weight, 
sc) for 10 days. 
 
Chemical and reagents 
Pure ursolic acid was purchased from Yucca 
Enterprises, Mumbai, India. Commercially available 
cyclophosphamide was purchased from Zydus 
Oncosciences, Ahmedabad, India. Commercial kits 
for estimation of biomarkers were procured from 
Crest Biosystems, Goa, India (CK-MB, CK-NAC, 
LDH, AST, and ALT) and from Robonik India Pvt. 
Ltd., Thane, India (TG and TC). Other chemicals and 
reagents were of highest analytical grade. 
 
Dose selection  
Several studies conducted on URSO were taken 
into consideration during dose selection for the 
present study. Two studies conducted by Saravanan 
R. and others24,35 utilized three doses: 10, 20 and 40 
mg/kg of URSO in wistar rats and evaluated the 
protective effect after sub-chronic administration of 
the phytoconstituent. Other study by Radhiga T.36 
proved protective effect of the phytoconstituent at 40 
mg/kg after 7 days of administration. Acute toxicity 
studies were deemed not necessary due to availability 
of abundant data from previously conducted 
studies37,38. Considering the present experimental 
model of 10 days, 40 mg/kg by sc route was selected. 
The dose of 200 mg/kg ip for CYP was selected on 
the basis of similar experimental models in published 
literature39,40. Dose volume for subcutaneous 
administration was 5 ml/kg and for intraperitoneal 
administration was 10 mL/kg41.  




General observations and mortality 
Animals were observed once daily for occurrence 
of any clinical signs and twice daily for morbidity or 
mortality. Cage-side observation was performed daily 
during clinical signs observation and if any 
abnormalities were found, the animals were removed 
from the cage and observed individually. 
 
Body weight and heart weight measurement 
Body weight was measured on Day 1 and Day 10 
of the treatment period and percentage change in body 
weight was reported. Heart weights were immediately 
recorded from sacrificed animals after cleaning the 
organs with saline and tissue paper. A ratio of heart 




Animals were anesthetized with the combination of 
ketamine (75 mg/kg, i.p.) and xylazine (8 mg/kg, i.p.) 
prior to ECG measurement on Day 10. A digital 
physiograph (Model: DI-2, INCO, Ambala, India) 
was used to record the cardiogram. Heart rate, QRS, 
QT, PR and RR intervals were determined from Lead 
II of the cardiogram. 
 
Biochemical Analysis 
Animals were fasted overnight prior to blood 
collection and necropsy. Blood was collected under 
anaesthesia from the retro-orbital plexus. Aspartate 
aminotransferase (AST), alanine aminotransferase 
(ALT), creatine kinase-MB (CK-MB), creatine 
kinase-NAC (CKNAC) and lactate dehydrogenase 
(LDH), serum cholesterol and triglyceride levels were 
estimated by using commercial kits with the help of a 
semi auto analyzer (Model: Prietest TOUCH, 
Robonik (India) Pvt. Ltd.). 
 
Tissue antioxidant enzymes 
Hearts were collected from each animal and 
weighed after cleaning with saline and tissue paper. 
They were homogenized with 0.9% buffered KCl (pH 
7.4) solution and centrifuged at 5000 rpm for 15 min. 
The supernatant was decanted and used for the 
estimation of superoxide dismutase (SOD), catalase 
and reduced glutathione (GSH) by colorimetric 
methods. SOD activity was determined on the 
capacity of the enzyme to reduce nitroblue 
tetrazolium. The absorbance was measured at 560 
nm42. Ellman’s method was followed for the 
estimation of GSH. The method is based on the 
reaction between GSH and 2-nitrobenzoic acid to 
form a yellow colored compound that has absorbance 
at 412 nm43. Catalase was estimated by method of 
Aebi44, based on the decomposition of hydrogen 
peroxide and the change in absorbance was measured 
at 240 nm. 
 
Histopathological analysis 
After weighing the hearts, representative parts from 
the organs were removed and fixed in 10% formalin. 
Sections were 5µm thick and H&E stained before 
evaluation. Damage and severity to the myocardium 




InStat data analysis program was used for 
statistical analysis (GraphPad Software, USA). Data 
were analysed by one-way analysis of variance 
(ANOVA) and presented as means±standard 
deviation (SD). Individual differences were 
determined by Tukey multiple comparison tests. A 
value of less than 0.05 was considered statistically 
significant.  Types of Comparisons: 
1. Normal control group vs CYP 
control/CYP+URSO group marked by */**/*** 
2. CYP control group vs CYP+URSO group 




General observations and mortality 
All animals were observed daily for occurrence of 
clinical signs. No physical abnormal changes or 
mortality was observed in control and treated groups.  
 
Body weight, heart weight and heart to body weight ratio 
In the CYP treated group, body weight of the 
animals was found to be significantly decreased when 
compared to control group. Treatment with ursolic 
acid reverted most of the changes and produced a 
moderately significant increase in body weight. CYP 
treated group showed a remarkable increase in heart 
weight, believed to be due hypertrophy of the heart. 
Treatment with URSO normalised the heart weight 
and heart weight/body weight ratio when compared to 
CYP Control group (Table 1). 
 
Electrocardiographic parameters 
The CYP control group demonstrated a significant 
increase in Heart Rate, RR segment, QT segment, PR 
interval and QRS interval compared with the normal 
control. Ursolic acid pre-treatment almost normalised 
all of the parameters (Table 2).  





CYP Control group displayed rise in serum 
biomarker values compared to concurrent normal 
control group.  Treatment group CYP+URSO showed 
a marked reduction in AST, ALT, CK-MB, CK-NAC 
and LDH values (Fig. 1). 
 
Lipid profile assay 
TG and TC level showed marked increase in toxic 
control group in comparison to normal. Ursolic acid 
treated group showed normalization in serum vales of 
TC and TG (Table 3).  
 
Tissue antioxidant enzymes 
CYP treatment caused reduction in heart tissue 
homogenate (HTH) levels of SOD, Catalase and 
GSH. Ursolic acid treated animals displayed 
significantly higher values compared to CYP control 
group animals (Table 3). 
 
Histopathological analysis 
Myocardial cells of the animals in normal control 
and URSO groups showed normal texture and intact 
cell membranes. Animals in the CYP Control group 
showed changes such separation of myocardial tissue, 
vacuolization of myocardial cells, and accumulation 
of inflammatory cells and loss of myofibril. 
Treatment with Ursolic acid in the CYP+URSO 
group, showed decreased infiltration of inflammatory 
cells, lesser defragmentation, vacuolization and 
myofibril loss (Fig. 2). 
 
Table 1 — Effects on physical parameters 
Treatment Body Weight (g) Heart Weight 
(g) 
Heart/Body Weight 
Ratio (x10-4) Day 1 Day 10 % Change 
Normal Control 220.17±2.76 259.74±2.64 15.24 0.72±0.01 27.33 
CYP 225.73±2.78 190.83±3.19*** -18.35 1.16±0.03*** 60.26*** 
URSO 222.51±2.91 259.00±2.18 14.08 0.74±0.02 28.18 
CYP+URSO 217.83±2.37 196.00±2.80***## -11.21 0.90±0.01***### 53.06***### 
Results are expressed as mean ± SD, n=6. ***p<0.001 when compared to normal, ###p<0.001, ## p<0.01, when compared to CYP 
treated. CYP – Cyclophosphamide, URSO – Ursolic Acid 
 
Table 2 — Effects on Heart Rate and Electrocardiographic parameters 
Treatment Heart Rate (bpm) RR (ms) QRS (ms) QT (ms) PR (ms) 








































Results are expressed as mean ± SD, n=6. ***p<0.001 when compared to normal, ###p<0.001 when compared to CYP treated. CYP:




Fig. 1 — Effect on serum biomarker levels 





Traditionally, herbs, spices and medicinal plants 
have been used since ages for purpose of cosmetic, 
culinary and therapeutic intentions. Polyphenols and 
triterpenoids are the active antioxidant principles of 
most fruits, herbs and spices used in daily life. There 
has been a keen interest in utilizing them for 
therapeutic purposes2,45. In addition to antioxidant 
effects, these active principles, alone or in 
combination with other constituents, display a 
magnitude of pharmacological activities such as 
hepatoprotective, antidiabetic, antibacterial, 
anticancer, etc46–50. These active principles inhibit 
oxidative damage of DNA through free radicals. ROS 
induce changes in gene expression causes generation 
of abnormal proteins resulting in diseases and 
aging51,52. Hence, they prove to be highly effective 
means to treat and prevent disorders of such origin.  
Ursolic acid is found in abundant quantities in apple 
peels. Other major sources of the phytoconstituent 
include: basil, cranberries, peppermint, and prunes53. 
Various studies have demonstrated the efficacy of 
these principles in preventing ailments like 
cardiomyopathy caused by oxidative stress54. We 
have evaluated the possible protective effect of ursolic 
acid against chemotherapy-induced cardio-toxicity in 
this study. 
Single dose of cyclophosphamide caused marked 
rise in heart weight and decrease in body weight of 
the animals indicating that the normal metabolic 
functions were disordered, a sign of 
cyclophosphamide toxicity39. Increased heart weight 
can be reasoned to edema and necrotic myocardial 
tissues51. Treatment with ursolic acid improved 
overall metabolic functions, normalized body weight, 
and heart weight in the treated animals.  
Cyclophosphamide causes direct damage to the 
myocardial endothelium by causing extravasation of 
plasma proteins and infiltration of erythrocytes into 
myocardial interstitium and muscle cells52. Damaged 
cell membrane allows biomarkers: CKNAC, 
isoenzyme CKMB (cardiac muscle fraction of CK), 
LDH, AST and ALT to leak into systemic circulation.  
Increased cellular permeability and damage to 
functional integrity of the cardiac tissue leads to 
myocardial necrosis. An estimate of damage to the 
myocardium can be assessed by quantification of 
these biomarker enzymes from blood55. CYP control 
group showed higher serum levels of these 
biomarkers, confirming the cardiotoxicity induced by 
CYP. Administration of ursolic acid resulted in 
reduction of levels of biomarkers in blood36, This 
effect can be attributed to the membrane stabilizing 
action of the phytoconstituent.  
Acrolein, the toxic metabolite of CYP generates 
ROS that causes damage to the surrounding tissue51. 
This is mediated by mitochondrial dysfunction and 
increased intracellular calcium that in turn activates 
xanthine oxidase, which stimulates production of 
more ROS and depletion in glutathione56. Free 
radicals such as superoxide ion, hydroxyl radical  
(OH-), alkoxyl and peroxyl radicals, and hydrogen 
 
Table 3 — Effects on total cholesterol & triglycerides and heart tissue homogenate levels of SOD, catalase and GSH 
Treatment Blood Serum Level (mg/dL) Heart Tissue Homogenate (U/L) 
TC TG SOD Catalase GSH 
Normal Control 21.76±1.36 79.61±3.81 87.46 ±3.98 57.78 ± 5.20 87.90 ± 4.78 
CYP 74.46±3.6*** 205.57±7.15*** 17.99 ± 0.01*** 16.24 ± 0.35*** 24.49 ± 0.49*** 
URSO 33.14±3.37 83.41±2.03 61.63 ± 3.99 45.25 ± 2.61 69.56 ± 5.29 
CYP+URSO 42.85±1.94***### 157.52±6.94***### 55.17 ±0.47**### 38.81 ± 0.27**### 54.06 ± 0.86***## 
Results are expressed as mean ± SD, n=6.  **p<0.01***p<0.001 when compared to normal control group, ##p<0.01, ###p<0.001 when





Fig. 2 — Photomicrographs (X400) of heart tissues in (A) Normal
control (B) CYP control (C) Ursolic acid control (D) CYP+URSO
treatment groups 
 




peroxide (H2O2) oxidizes polyunsaturated fatty acids 
(PUFA), proteins, cellular DNA and sterols52. These 
free radicals generated through CYP metabolism 
cause increase in lactoperoxidase activity and 
decrease in activity of cellular antioxidants57,58. 
Protective antioxidant enzymes such as SOD and 
CAT are present in lower levels in the heart compared 
to other body tissues making it more vulnerable to 
oxidative stress as H2O2 inhibits SOD and superoxides 
inhibit CAT functions58. These tissue antioxidants 
remove oxygen (O2) and hydrogen peroxide (H2O2) 
before they can interact to form more reactive 
hydroxyl radicals59. Inhibition of SOD and CAT leads 
to increased free radicals induced damage in cardiac 
tissues. In this study, marked decrease in levels of 
SOD and CAT was observed in heart tissue 
homogenate, a result of CYP toxicity. Treatment with 
ursolic acid resulted in increase in amount of these 
enzymes, thereby improving the antioxidant status 
and preventing cardiac damage. GSH (reduced 
glutathione) is another important regulator of cellular 
redox state56. CYP-induced decrease in tissue GSH 
was observed in this study which maybe a result of 
binding of CYP metabolites to free or protein bound 
tissue –SH groups60. These conjugates hinder the 
normal functions of the antioxidant. Acrolein is 
known to deplete GSH, GSH-linked glutathione-S-
transferases, and aldose reductase and thereby 
preventing detoxification of reactive aldehydes20,60. In 
this study, marked decrease in HTH levels of GSH 
was observed. Treatment with ursolic acid resulted 
normalized the HTH levels of GSH.  
Cyclophosphamide-induced hyperlipidemia is 
caused by inhibition of lecithin cholesterol acyl 
transferase (LCAT) and lipoprotein lipase (LPL) 
enzymes51. LCAT esterifies free cholesterol in serum 
and tissues and is vital in remodeling of HDL 
lipoproteins. LPL mostly found in adipose tissue and 
myocardial capillaries clears triglycerides from 
plasma, turning into free fatty acids and glycerol51. 
CYP-treatment causes an increase in total cholesterol, 
free cholesterol, free fatty acids and triglycerides51. 
Our observations were consistent with previous 
findings on CYP toxicity. Ursolic acid treatment 
reversed the toxic increase of TC and TG in serum. 
This effect of the phytoconstituent may be attributed 
to its anti-lipase, lipolytic, and PPAR-α agonist 
activity8,29. 
Cyclophosphamide administration diminished the 
heart rate and increased QT, QRS, PR and RR 
intervals. This effect on heart rate maybe due to 
increased secretion of acetylcholine at the neuro-
muscular junctions, which results in bradycardia. 
Elongation of QT interval is due to hypokalemia 
caused by blockade of the potassium channels. 
Release of acetyl choline causes change in 
parasympathetic tone and conduction system of the 
heart, leading to AV block causing elongation of PR 
interval61–63. Ursolic acid successfully prevents CYP 
induced bradycardia and normalizes the intervals4  
indicating its protective effect.  
Cyclophosphamide treated group showed 
vacuolization of myocytes, infiltration of leukocytes 
and other inflammatory cells, disruption of 
myocardial tissue and myofibril as reported 
previously64. It is known that upregulation of NF-κB 
mediates inflammation in the tissues through pro-
inflammatory cytokines like TNF-α, IL-6, and IL-1β 
which lead to fibrosis and myocardial disruption65,66. 
Ursolic acid treatment showed normalization of those 
pathological changes possibly by vasodilatation and 
restoration of the antioxidant enzymes.  
 
Conclusion 
Patients that suffer from cancer are at a risk of 
developing heart diseases like cardiomyopathy, IHD, 
and arrhythmias due to chemotherapy. Management 
of drug-related cardiomyopathy calls for an 
interdisciplinary approach. In present study, a single, 
high dose of cyclophosphamide caused marked 
myocardial tissue damage mediated through oxidative 
stress causing deleterious effects on biochemical and 
histopathological parameters in rats. Ursolic acid 
ameliorated the compromised myocardium by 
scavenging free radicals, reversing drug induced 
hyperlipidemia and strengthening antioxidant defense 
systems of tissues. These observations support the 
hypothesis of using the phytoconstituent, ursolic acid, 
as an adjunct therapy in management of 
cyclophosphamide-induced cardio-toxicity.  
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